Skip to content

A study to confirm the effect of lactic acid bacteria intake on improving immune function - Randomized, double-blind, placebo-controlled, parallel-group comparison study -

A study to confirm the effect of lactic acid bacteria intake on improving immune function - Randomized, double-blind, placebo-controlled, parallel-group comparison study - - A study to confirm the effect of lactic acid bacteria intake on improving immune function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052818
Enrollment
300
Registered
2025-06-30
Start date
2024-01-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Sponsors

KSO Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy Japanese males and females from 20 to 65 years old. 2) Subjects who have received sufficient explanation of the purpose and content of the study, have the capacity to consent, have voluntarily volunteered to participate based on a good understanding of the study, and have agreed to participate in the study in writing.

Exclusion criteria

Exclusion criteria: Subjects-- 1) suffering from, undergoing treatment, or with a history of diabetes, renal or hepatic disease, or other serious illness, thyroid disease, adrenal gland disease, psychiatric disease, autoimmune disease, or other metabolic disease. 2) who cannot stop taking foods containing lactic acid bacteria, bifidobacteria, oligosaccharides, or other viable bacteria during the study period. 3) who regularly use foods that may affect immunity. 4) who constantly consumes more than the appropriate amount of alcohol. 5) who are unable to abstain from alcohol for 2 days prior to each test. 6) who have declared having food allergies. 7) with a history of gastrointestinal diseases or gastrointestinal surgery (except appendicitis). 8) who are pregnant, breast feeding, or planning to be pregnant during the study period. 9) with a history or current history of drug or alcohol dependence. 10) who are participating or intend to participate in other studies involving the use of other foods, drugs or cosmetics. 11) who regularly use medicines that may affect immunity, or who are unable to stop taking them during the study period. 12) with hay fever, atopic dermatitis, allergic rhinitis, bronchial asthma, or chronic bronchitis. 13) who plan to visit the hospital or take/use prescription medication annually due to hay fever or allergic rhinitis. 14) who have oral problems that involve bleeding, or plan to undergo dental or oral treatment. 15) who engage in strenuous exercise. 16) who plan to travel abroad during the study period. 17) who have taken antibiotics within 1 month of the screening test. 18) who smoke. 19) who are diagnosed as anemic by screening tests and are not suitable for blood sampling. 20) who have donated blood drawn or component blood more than 200 mL within 1 month or 400 mL within 3 months prior to the date of obtaining consent. 21) who work in day and night shifts, late at night, or who are full telecommuters or blue-collar workers.

Design outcomes

Primary

MeasureTime frame
cold-like symptoms questionnaire

Secondary

MeasureTime frame
mDC activity, salivary sIgA, NK cell activity, CD8+T cell activity, CD4+T cell activity, B cell activity intestinal condition questionnaire, SF-36, stress and other things measured by visual analog scale (VAS), OSA sleep inventory MA version (OSA-MA)

Countries

Japan

Contacts

Public ContactEiji Yoshikawa

KSO Corporation Clinical Trial Management department

eigyou@kso.co.jp03-3452-7733

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026